Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
739 participants
INTERVENTIONAL
2010-10-31
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objective:
* To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric mean titer (GMT) ratios for each of the four virus strains separately among subjects 65 years of age and older
Observational Objective:
* To describe the safety profiles of TIV among subjects 18 years of age and older and QIV in subjects 65 years and older, as assessed by solicited injection site and systemic adverse events (AEs) collected for 7 days post-vaccination, unsolicited adverse events collected from 21 days post-vaccination, and adverse events of special interest and serious adverse events (SAEs) collected from Visit 1 to Visit 2.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: Investigational Quadrivalent Influenza Vaccine
Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Group 2: Investigational Trivalent Influenza Vaccine
Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine
Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine
Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Investigational Trivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
0.5 mL, Intramuscular
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent form (ICF) has been signed and dated.
* Able to attend all scheduled visits and to comply with all trial procedures.
* For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks post-vaccination.
Exclusion Criteria
* Currently breastfeeding a child.
* History of serious adverse reaction to any influenza vaccine.
* Receipt of any vaccine in the 4 weeks preceding the trial vaccination.
* Planned receipt of any vaccine between Visit 1 and Visit 2.
* Participation in another interventional clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first study vaccination or during the course of the study.
* Receipt of any influenza vaccine since 01 August 2010 (including 2009 H1N1 monovalent vaccine).
* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances.
* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.
* Thrombocytopenia, bleeding disorder, or receipt of anticoagulants contraindicating intramuscular vaccination.
* Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine.
* Personal history of Guillain-Barré Syndrome (GBS).
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
* Any chronic illness that, in the opinion of the Investigator, is not well controlled or that may interfere with trial conduct or completion or with assessment of adverse events.
* Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
* Current alcohol or drug use that, in the opinion of the Investigator, might interfere with the ability to comply with trial procedures.
* Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi Pasteur, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Sanofi Pasteur Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hoover, Alabama, United States
South Miami, Florida, United States
Springfield, Missouri, United States
New York, New York, United States
Rochester, New York, United States
Cincinnati, Ohio, United States
Allentown, Pennsylvania, United States
Bensalem, Pennsylvania, United States
Warwick, Rhode Island, United States
Mt. Pleasant, South Carolina, United States
Nashville, Tennessee, United States
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UTN: U1111-1113-3619
Identifier Type: OTHER
Identifier Source: secondary_id
QIV03
Identifier Type: -
Identifier Source: org_study_id